PvP Biologics, Inc.

Novel therapeutics for Celiac Disease

PvP Biologics was spun-out of the University of Washington’s Institute for Protein Design in 2016 by lead investigator Ingrid Swanson Pultz together with Adam Simpson and Malcom Hill. PVP is developing a computationally-engineered, highly potent super glutenase for the treatment of uncontrolled celiac disease. The lead therapeutic, Kuma062, is a protein that degrades ingested gluten that can lead to inflammation and damage in the small intestine. PvP was acquired by Takeda Pharmaceutical Company in February 2020.